Membranous Nephropathy
39
13
15
14
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.3%
4 terminated out of 39 trials
77.8%
-8.8% vs benchmark
10%
4 trials in Phase 3/4
21%
3 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (39)
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Belimumab With Rituximab for Primary Membranous Nephropathy
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
MOR202 for Refractory MN
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
NEPTUNE Match Study
Nephrotic Syndrome Study Network
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
An Outcome Analysis of Primary Membranous Nephropathy
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
Autoreactive B Cells in Membranous Nephropathy
Omics of Rituximab-resistance
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis